CompletedPhase 3

The Use of Liraglutide in Brain Death

Randomized Clinical Trial to Evaluate the Use of Liraglutide in Individuals With Brain Death and Anti-inflammatory and Anti-apoptotic Effects on Organs to be Transplanted

Lead sponsor

Hospital de Clinicas de Porto Alegre

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Brain Injuries

Eligibility highlights

Primary endpoint

•Change inflammation

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03672812

Org study ID87650318100005327

Timeline

Milestones

Study start2018-09-01actual

Study first posted2018-09-17actual

Primary completion2019-12-10actual

Study completion2022-02-10actual

Last update posted2024-03-05actual

Assets

Investigational agents

Liraglutide

Who this study enrolls

Brain Injuries

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•individuals deceased more than 18 years after the end of the brain death protocol

Exclusion criteria

•Pregnant women, patients with advanced renal failure on hemodialysis, with hepatic insufficiency or allergy known to liraglutide

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

5 endpoints

Primary/protocol endpoint/low confidence

change inflammation

Time frame:from 6 hours to 24 hours